近日，上海证券交易所（上交所）向深圳亚辉龙生物科技股份有限公司（简称“亚辉龙”）下发问询函，要求其就2023年年度报告中的多项财务与经营事项作出进一步说明。问询内容主要聚焦于公司营业收入与净利润变动不匹配、毛利率显著高于同行业平均水平、应收账款大幅增长以及研发费用资本化处理等关键问题。上交所特别关注亚辉龙是否存在通过会计政策调节利润、虚增收入或资产质量下滑等风险。作为一家主营体外诊断试剂及仪器的高新技术企业，亚辉龙近年来业绩快速增长，但其财务数据的合理性与可持续性引发监管关注。此次问询体现了上交所对上市公司信息披露质量的严格把关，旨在保护投资者权益、维护市场公平透明。公司需在规定期限内对问询事项逐一回复，并可能根据情况补充披露相关信息。市场普遍认为，此举有助于提升企业治理水平，也有利于引导投资者理性判断公司真实价值。
Recently, the Shanghai Stock Exchange (SSE) issued an inquiry letter to Shenzhen Yahuilong Biotechnology Co., Ltd. (“Yahuilong”), requesting further clarification on several financial and operational matters disclosed in its 2023 annual report. The inquiry primarily focuses on discrepancies between revenue and net profit trends, gross margins significantly higher than industry averages, a substantial increase in accounts receivable, and the capitalization of R&D expenses. The SSE expressed particular concern over potential risks such as earnings manipulation through accounting policies, inflated revenue recognition, or deteriorating asset quality. As a high-tech company specializing in in vitro diagnostic reagents and instruments, Yahuilong has reported rapid growth in recent years; however, the reasonableness and sustainability of its financial performance have drawn regulatory scrutiny. This inquiry underscores the SSE’s commitment to ensuring high-quality disclosure by listed companies, protecting investor interests, and maintaining market transparency and fairness. Yahuilong is required to respond to all inquiries within a specified timeframe and may need to provide additional disclosures as necessary. Market observers generally view this regulatory action as conducive to improving corporate governance and helping investors make more informed assessments of the company’s true value.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/9638.html